Veronique D
- Novartis (NYSE:NVS) on Tuesday stated that Coartem (artemether-lumefantrine) Child has been authorised by Swissmedic as the primary malaria medication for newborns and younger infants.
- The brand new therapy, often known as Riamet Child in some international locations, was developed in collaboration with Medicines for
